| First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229, 2018 | 2847 | 2018 |
| Detection and localization of surgically resectable cancers with a multi-analyte blood test JD Cohen, L Li, Y Wang, C Thoburn, B Afsari, L Danilova, C Douville, ... Science 359 (6378), 926-930, 2018 | 2437 | 2018 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 867 | 2021 |
| Integrating genomic features for non-invasive early lung cancer detection JJ Chabon, EG Hamilton, DM Kurtz, MS Esfahani, EJ Moding, H Stehr, ... Nature 580 (7802), 245-251, 2020 | 494 | 2020 |
| Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, ... Journal of Clinical Oncology 39 (6), 619-630, 2021 | 479 | 2021 |
| Mesothelioma: Scientific clues for prevention, diagnosis, and therapy M Carbone, PS Adusumilli, HR Alexander Jr, P Baas, F Bardelli, A Bononi, ... CA: a cancer journal for clinicians 69 (5), 402-429, 2019 | 426 | 2019 |
| PD-1 restrains radiotherapy-induced abscopal effect SS Park, H Dong, X Liu, SM Harrington, CJ Krco, MP Grams, ... Cancer immunology research 3 (6), 610-619, 2015 | 383 | 2015 |
| Representation of minorities and women in oncology clinical trials: review of the past 14 years N Duma, J Vera Aguilera, J Paludo, CL Haddox, M Gonzalez Velez, ... Journal of oncology practice 14 (1), e1-e10, 2018 | 344 | 2018 |
| Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer AS Mansfield, MC Aubry, JC Moser, SM Harrington, RS Dronca, SS Park, ... Annals of Oncology 27 (10), 1953-1958, 2016 | 341 | 2016 |
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ... The lancet oncology 22 (7), 959-969, 2021 | 337 | 2021 |
| Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ... The lancet Diabetes & endocrinology 9 (8), 491-501, 2021 | 271 | 2021 |
| B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis AS Mansfield, AC Roden, T Peikert, YM Sheinin, SM Harrington, CJ Krco, ... Journal of thoracic oncology 9 (7), 1036-1040, 2014 | 246 | 2014 |
| Current diagnosis and management of small-cell lung cancer S Wang, S Zimmermann, K Parikh, AS Mansfield, AA Adjei Mayo Clinic Proceedings 94 (8), 1599-1622, 2019 | 235 | 2019 |
| Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers D Xie, R Marks, M Zhang, G Jiang, A Jatoi, YI Garces, A Mansfield, ... Journal of Thoracic Oncology 10 (8), 1213-1220, 2015 | 149 | 2015 |
| First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, ... Annals of oncology 33 (5), 488-499, 2022 | 147 | 2022 |
| Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial AS Mansfield, A Każarnowicz, N Karaseva, A Sánchez, R De Boer, ... Annals of oncology 31 (2), 310-317, 2020 | 146 | 2020 |
| Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer AS Mansfield, AJ Tafur, CE Wang, TV Kourelis, EM Wysokinska, P Yang Journal of Thrombosis and Haemostasis 14 (9), 1773-1778, 2016 | 140 | 2016 |
| Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer AS Mansfield, SJ Murphy, T Peikert, ES Yi, G Vasmatzis, DA Wigle, ... Clinical cancer research 22 (9), 2177-2182, 2016 | 140 | 2016 |
| Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011 EAL Enninga, JC Moser, AL Weaver, SN Markovic, JD Brewer, ... Cancer medicine 6 (10), 2203-2212, 2017 | 135 | 2017 |
| Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer AS Mansfield, PS Heikkila, AT Vaara, KAJ von Smitten, JM Vakkila, ... BMC cancer 9, 1-10, 2009 | 135 | 2009 |
Haidong Dong, MD, PhD.Professor of Immunology, Mayo Clinic在 mayo.edu 的电子邮件经过验证
